Abstract
The chemical heterogeneity of the group of agents known as the Ca2+ channel blockers or Ca2+ channel antagonists (Figure 1) has long suggested that these agents impair Ca2+ channel function by different mechanisms (for reviews see references 1 and 2). Accordingly, these agents exhibit important differences in their pharmacologic properties including variations in cardiac:smooth muscle selectivity (3,4) and differences in the extent to which they exhibit frequency- or use-dependence. Thus, verapamil/D600 and diltiazem are approximately equieffective in smooth and cardiac muscle, whereas nifedipine, and other 1,4-dihydropyridines, are significantly more selective for smooth muscle, both vascular and nonvascular (3–5). Similarly, verapamil/D600 and diltiazem exhibit to a significant degree the phenomena of use- and voltage-dependence whereby activity increases with increasing frequency of stimulation and with increasing membrane depolarization. This suggests that verapami1/D600 and diltiazem, unlike nifedipine, have a marked preference for interaction with channels in the open or depolarized state (6). Additionally, verapami1/D600 and diltiazem interact with a number of receptor systems, including muscarinic, adrenergic α1 and α2 and opiate, as well as with K+ channels, at concentrations (10-6M) that are similar to those achieved clinically (for reviews see references 1,2,7). In contrast nifedipine is relatively free from such additional actions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Janis RA, Triggle DJ: New developments in Ca2+ channel antagonists. J Med Chem (26): 776–785, 1983.
Trigqle DJ, Swamy VC: Calcium antagonists. Some chemical- pharmacologic aspects. Circ Res (52: Suppl. I): 17–28, 1983.
Fleckenstein A: Calcium antagonism in heart and smooth muscle. Experimental facts and therapeutic prospects. Wiley and Sons, Inc., New York, N.Y., 1983.
Henry PD: Comparative cardiac pharmacology of calcium blockers. In: Flaim SF and Zelis R (Eds) Calcium blockers. Mechanisms of action and clinical applications. Urban and Schwarzenberg, Baltimore, 1982, pp. 135–154.
Flaim SF: Comparative pharmacology of calcium blockers based on studies of vascular smooth muscle. In: Flaim SF and Zelis R (Eds) Calcium blockers. Mechanisms of action and clinical applications. Urban and Schwarzenberg, Baltimore, 1982, pp. 155–178.
Lee KS, Tsien RW: Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in sinqle dialysed heart cells. Nature (302): 790–794, 1983.
Triggle DJ: Chemical pharmacology of calcium antagonists. In: Rahwan RG and Witiak D (Eds) Calcium regulation by calcium antagonists. American Chemical Society, Washington, D.C., 1982, pp. 17 - 37.
Triggle DJ, Janis RA: Ca2+ channel antagonists. New perspectives from the radioligand binding assay. In: Back N and Spector S (Eds) Modern Methods in Pharmacology, Vol. II, Alan R. Liss, Inc., New York, N.Y., 1983, in press.
Böiger GT, Gengo P, Klockowski R, Luchowski E, Siegel H, Janis RA, Triggle AM, Triggle DJ: Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea pig ileal smooth muscle. J Pharmacol Exptl Therap (22): 291–309, 1983.
Triggle DJ, Janis RA: Nitrendipine: binding sites and mechanisms of action. In: Scriabine A, Vanov S and Deck K (Eds) Nitrendipine. Urban and Schwarzenberg, Baltimore, 1983, in press.
Luchowski EM, Yousif F, Triggle DJ, Maurer SC, Sarmiento JG,Janis RA: The effects of metal cations and calmodulin antagonists on [3H]nitrendipine binding in smooth and cardiac muscle. Submitted for publication.
Fosset M, Jaimovich E, Delpont E, Lazdunski M: [3H]Nitrendipine receptors in skeletal muscle. Properties and preferential localization in transverse tubules. J Biol Chem (258): 6086–6092, 1983.
Bellemann P, Schade A, Towart R: Dihydropyridine receptor in rat brain labeled with [3H]nimodipine. Proc Nat Acad Sei USA (80): 2356–2360, 1983.
Mannhold R, Rodenkirchen R,Bayer R: Qualitative and quantitative structure-activity relationships of specific Ca antagonists. Prog Pharmacol (5): 25–52, 1982.
Nachshen DA, Blaustein MP: The efects of some organic “calcium antagonists” on calcium influx in presynaptic nerve terminals. Mol Pharmacol (16): 579–586, 1979.
Kaplita PV, Triggle DJ: Actions of Ca2+ antagonists on the guinea pig ileal myenteric plexus preparation. Biochem Pharmacol (32): 65–68, 1983.
Triggle DJ: Ca2+ channels revisited: problems and promises. Trends in Pharmacol Sei, in press, 1983.
Gengo PJ, Luchowski EM, Rampe DE, Rutledge A, Triggle AM, Triggle DJ, Janis RA: Chemical and pharmacological approaches to the definition and quantitation of Ca++ channels. In: Watson JD (Ed) Cold Spring Harbor Symposium on Molecular Neurobiology. Cold Spring Harbor, New York, in press.
Bean BP, Nowycky MC, Tsien RW: Electrical estimates of Ca channel density in heart cell membranes. Biophys J (41): 295a, 1983.
Murphy KMM, Gould RJ, Largent BL, Snyder SH:A unitary mechanism of calcium antagonist drug action. Proc Nat Acad Sei USA (80): 860–864, 1983.
Glossmann H, Ferry DR, Lübbecke F, Mewes R, Hofmann F: Identification of voltage operated calcium channels by binding studies: differentiation of calcium antagonist drugs with 3H-nimodipine radioligand binding. J Recept Res (3): 177–190, 1983.
Norman RI, Borsotto M, Fosset M, Lazdunski M, Ellory JC: Determination of the molecular size of the nitrendipine-sensitive Ca2+ channel by radiation inactivation. Biochem Biophys Res Comm (111): 878–883, 1983.
Venter JC, Fraser CM, Schaber JS, Yung CY, Böiger G, Triggle DJ: Molecular properties of the slow inward calcium channel. J Biol Chem (258): 9344–9348, 1983.
Gould RJ, Murphy KMM, Snyder SH: 3H-Nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists. Proc Nat Acad Sei USA (79): 3656–3660, 1982.
Hagiawara S, Byerly L: Calcium channel. Ann Rev Neuroscience (4): 69–125, 1981.
Schramm M, Thomas G, Towart R, Franckowiak G: Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature (303): 535–537, 1983.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Triggle, D.J., Janis, R.A. (1984). Calcium Channel Antagonists: Pharmacologic and Radioligand Binding Approaches to Mechanisms of Action. In: Sperelakis, N., Caulfield, J.B. (eds) Calcium Antagonists. Developments in Cardiovascular Medicine, vol 39. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3810-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3810-9_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3812-3
Online ISBN: 978-1-4613-3810-9
eBook Packages: Springer Book Archive